Abstract 209P
Background
Immune-cell indices of immunohistochemistry (IHC) are calculated in countless research studies; often to identify prognostic or predictive biomarkers in cancer patients. The study aimed to investigate how the location of immune cells and the amount of tumor epithelia may affect their calculation in breast cancer (BC) patients whilst exploring multiple sample techniques for IHC immune-cell quantification.
Methods
Formalin-fixed, paraffine-embedded pretreatment tumor tissue (N=227; full-cut slides) from BC patients was stained with two multiplexed chromogenic IHC using CK7/19, CD8, CD4, FOXP3, CD20, CD66b, and CD68. AI-powered image analysis (U-net) determined their area-based indices in the reference spaces: total tumor area, tumor stroma, tumor epithelia, a stromal tumor brim, and a fixed area for each lesion using multiple subsamples (mean no., 100) within tumor stroma (in total, 1 mm2) and epithelia (in total, 1 mm2).
Results
Immune cells were predominantly situated in tumor stroma and rarely epithelia (P<0.01). The most infiltrative cell type was CD68 with a mean index of 3% for epithelia, yet 32% for stroma. In remainder cells, indices were <0.7% for epithelia. The amount of epithelia ranged from 1-60%, which strongly affected index calculations that included the total area of epithelia (P<0.01). In addition, solidity of tumor islands was highly associated with the number of infiltrative CD8, CD66b, and CD68 cells (P<0.01).
Conclusions
The location (stroma vs epithelia) of each immune cell of interest should be considered in connection to its index calculation because the amount of tumor epithelia may skew the result. Alternatively, the novel, unbiased subsampling developed in this study could be used. High solidity meant fewer infiltrating cells, which, conceivably, may affect both prognostic and predictive utility of immune cells.
Legal entity responsible for the study
The authors.
Funding
Danish Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
Resources:
Abstract
156P - Liver Metastases Correlate with Shortened Survival and Increased Dissociate Response in Patients Treated with T-Cell Engagers.
Presenter: Noé Herbel
Session: Poster Display session
Resources:
Abstract
157P - Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Caroline Even
Session: Poster Display session
Resources:
Abstract
158P - XCR1+ dendritic cell (DC) role in antitumoral response to anti PD-L1 antibody: Data from the phase Ib/II trial of DC vaccination in small cell lung cancer patients
Presenter: Maria Gonzalez Cao
Session: Poster Display session
Resources:
Abstract
159P - Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
Presenter: Giada Sabatino
Session: Poster Display session
Resources:
Abstract
160P - Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results
Presenter: Domas Vaitiekus
Session: Poster Display session
Resources:
Abstract
161P - Safety of TrimelVax vaccine for patients with advanced melanoma: Clinical results
Presenter: ROBERTO ESTAY
Session: Poster Display session
Resources:
Abstract
162P - EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
Presenter: Romain Cohen
Session: Poster Display session
Resources:
Abstract
163P - Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Presenter: Elise Jirovec
Session: Poster Display session
Resources:
Abstract
164P - Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract